Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 12:107301.
doi: 10.1016/j.ahj.2025.107301. Online ahead of print.

Rationale and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial

Graham S Hillis  1 , Jarryd S K Walker  2 , Thomas Gilbert  3 , Charley A Budgeon  4 , John K French  5 , Joseph B Selvanayagam  6 , Vijay A Dhakshinamurthy  7 , Richard W Troughton  8 , Jorge Moragues  9 , Abdul R Ihdayhid  10 , Thomas J Ford  11 , Sarah Zaman  12 , Johanne Neill  13 , Philip D Adamson  14 , James Pemberton  15 , Erin Doherty  16 , Gillian A Whalley  17 , Kiran Sarathy  18 , David B Brieger  19 , Chiew Wong  20 , Lene H Nielsen  21 , Paul Maggiore  22 , Anthony S H Kueh  23 , Jithendra Somaratne  24 , Adil Rajwani  25 , Jocelyne Benatar  26 , Ralph A H Stewart  27
Affiliations
Free article

Rationale and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial

Graham S Hillis et al. Am Heart J. .
Free article

Abstract

Rationale: Left ventricular (LV) thrombus is a consequence of systolic dysfunction and is associated with an increased risk of stroke and systemic embolism. Anticoagulation with warfarin has been the standard of care. However, following the widespread adoption of direct oral anticoagulants (DOACs) in other settings, these are increasingly used to treat LV thrombus, despite limited randomized data to support equivalent outcomes and safety.

Primary hypothesis: We hypothesise that DOACs will be non-inferior to warfarin in the resolution of LV thrombus, without the occurrence of cardiovascular death, stroke, systemic embolism or major bleeding at 3-months.

Design: The REsolution of LEft VENTricular thrombus (RELEVENT) trial (ACTRN12618001254280) will test the non-inferiority of DOACs compared to warfarin. This prospective trial will randomize 216 patients with best-available imaging confirmed LV thrombus, at a 1:1 ratio to either warfarin or a DOAC, for a duration of 12-14 weeks. Any DOAC approved for stroke prevention in atrial fibrillation may be used, according to local preference. The primary endpoint will be the resolution of the thrombus, without the occurrence of cardiovascular death, stroke, systemic embolism or major bleeding at 3-month follow-up. Secondary and other endpoints of interest include components of the primary outcome, changes to thrombus volume and diameter, days alive and out of hospital, disability free survival and quality of life. Patients will be followed up for 3 years to obtain data on long-term management and outcomes.

Sites: Recruitment to the RELEVENT trial is underway in 16 centers in New Zealand and Australia.

Conclusions: The RELEVENT trial will help clarify whether DOACs are non-inferior to warfarin in the early treatment of left ventricular thrombus. It will also generate important insights into the long-term management and outcomes for patients.

Keywords: Left ventricular thrombus; direct oral anticoagulant; randomized clinical trial; warfarin.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LinkOut - more resources